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Abstract
Background: Detection of the mycobacterial cell wall antigen lipoarabinomannan (LAM) in urine can be used to diagnose
HIV-associated tuberculosis (TB) using a qualitative (positive/negative) read-out. However, it is not known whether the
quantity of LAM present in urine provides additional prognostic information.
Methods/Findings: Consecutively recruited adult outpatients initiating antiretroviral therapy (ART) in South Africa were
investigated for TB regardless of clinical symptoms using sputum smear microscopy and liquid culture (reference standard).
Urine samples were tested using the Clearview TB-ELISA for LAM and the Xpert MTB/RIF assay. The ELISA optical densities
(OD) were used as a quantitative assessment of urine LAM. Among 514 patients with complete sputum and urine LAM OD
results, culture-confirmed TB was diagnosed in 84 patients. Twenty-three (27.3%) were LAM-positive with a median LAM OD
of 0.68 (IQR 0.16–2.43; range, 0.10–3.29) and 61 (72.6%) were LAM negative (LAM OD ,0.1 above background). Higher LAM
ODs were associated with a range of prognostic indices, including lower CD4 cell counts, lower haemoglobin levels, higher
blood neutrophil counts and higher mycobacterial load as assessed using both sputum and urine samples. The median LAM
OD among patients who died was more than 6.8-fold higher than that of patients who remained alive at 3 months (P,
0.001). The small number of deaths, however, precluded adequate assessment of mortality risk stratified according to urine
LAM OD.
Conclusions: In patients with HIV-associated TB, concentrations of LAM in urine were strongly associated with a range of
poor prognostic characteristics known to be associated with mortality risk. Urine LAM assays with a semi-quantitative
(negative vs. low-positive vs. high-positive) read-out may have improved clinical utility over assays with a simple binary
result.
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Introduction
Tuberculosis remains the leading cause of mortality among
people living with HIV/AIDS (PLWHA) both in sub-Saharan
Africa and globally [1]. This is in part due to the non-specific
clinical presentation among HIV-infected patients such that much
TB disease remains undiagnosed and therefore untreated.
Diagnosis is further complicated by high rates of disseminated,
extra-pulmonary, sputum smear-negative and radiologically non-
specific disease [2–4]. Improved microbiological assays for the
detection of TB among PLWHA that are accurate, low-cost and
easy to implement at the point-of-care are therefore an important
public health priority [5–7].
Lipoarabinomannan (LAM) is a cell wall antigen of Mycobac-
terium tuberculosis that can be detected in urine, providing utility
for the diagnosis of HIV-associated TB [8], especially among those
with advanced immunosuppression [9–12]. Patients testing LAM-
positive have poor prognostic characteristics and clinical outcomes
[12–14] and the ability to detect LAM appears to be associated
with disease severity [15]. Assays for urine LAM may potentially
be useful in the diagnostic algorithm as a rule-in test for HIV-
associated TB and the evidence is due to be assessed by the World
Health Organisation (WHO) in 2014.
Two formats of LAM detection assays are currently commer-
cially available: an enzyme-linked immunosorbent assay (ELISA –
Clearview TB-ELISA, Alere Inc, Waltham, MA, USA) and a
simple, lateral flow, point-of-care assay Determine TB-LAM
(Alere Inc.). Both assay formats have a qualitative binary (positive
or negative) read-out. However, the LAM ELISA can also be used
to provide a quantitative read-out expressed as the optical density
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(OD) at 450 nm [16]. Evaluations of LAM ELISA have shown
very strong, correlations between the OD and concentration of
purified LAM [16]. However, little is known about whether LAM
quantification provides additional clinically useful information. We
therefore undertook this retrospective analysis of LAM ELISA
data from a cohort study in South Africa to determine the
relationship between LAM OD and markers of HIV disease
progression, other prognostic indices, mycobacterial burden, and
mortality.
Methods
The extremely high burden of TB among treatment-naı¨ve
patients at the antiretroviral treatment (ART) clinic in Gugulethu
Township, Cape Town has been previously characterised in detail
[17,18]. Written informed consent was provided by all patients
and the study was jointly approved by the ethics committees of the
University of Cape Town, Cape Town, South Africa, and the
London School of Hygiene & Tropical Medicine, London, UK.
Details of patient recruitment and laboratory procedures have
previously been reported in parent studies [9,19,20]. Eligible
patients were ART-naı¨ve adults aged .18 years without a current
TB diagnosis attending an ART centre in a Cape Town township
for treatment initiation. All patients received trimethoprim-
sulphamethoxazole prophylaxis.
Prospectively recruited patients had demographic details
recorded and a standardized symptom-screening questionnaire
completed prior to starting ART. Two sputum samples, one spot
and one induced sample [21], were obtained from all patients.
Additionally, all patients provided urine samples that were
collected in sterile containers and stored at 220uC within 3 hours
of collection. Venous blood was collected for measurement of CD4
cell counts and plasma viral load. We determined clinical
outcomes of patients up to 90 days during routine follow-up
within the ART service as previously described [13].
Procedures
Laboratory procedures have been described in detail elsewhere
[9,19]. In brief, sputum samples were processed in an accredited
laboratory and were decontaminated using N-acetyl-L-cysteine
and sodium hydroxide. Sputum was tested using fluorescence
microscopy and a ‘smear-positive’ result was defined by any smear
graded as scanty, 1+, 2+ or 3+. Sputum was also tested by liquid
culture using Mycobacterial Growth Indicator Tubes (MGIT,
Becton Dickinson, Sparks, Maryland, USA).
Stored urine samples were defrosted and retrospectively
analysed in duplicate for the presence of LAM using Clearview
MTB-ELISA (Alere Inc.), with strict adherence to the manufac-
ture’s instructions. OD readings were used to quantitatively
express urine LAM results. Each patient’s final OD was
determined by subtracting the mean negative control OD from
the mean patient sample reading with a minimum value of 0. A
positive LAM result was defined by an OD of at least 0.1 in
accordance with the manufacturer’s instructions. Defrosted urine
samples (2.0 mL) were also retrospectively tested using Xpert
MTB/RIF (Cepheid Inc, Sunnyvale, CA USA) according to
manufacturer’s instructions. C-reactive protein (CRP) concentra-
tions were measured in serum samples using the Quantikine
enzyme-linked immunosorbent assay (R&D Systems Inc., Minne-
apolis, MN, USA) per manufacturer’s instructions.
Definitions and analysis
A confirmed TB case was defined by a patient having
Mycobacterium tuberculosis cultured from one or more sputum
samples. Patient haemoglobin values were used to classify anaemia
according to WHO criteria [22]. Patients were grouped into one
of three mutually exclusive groups according to their urine LAM
result and corresponding LAM OD where patients were urine
LAM-negative, urine LAM-positive with a low OD (OD,0.50) or
urine LAM-positive with a high OD (OD$0.50) as this cut-off
approximated to the median. Proportions were compared using
either chi-squared tests or Fisher’s exact tests as indicated and
medians were compared using Kruskal-Wallis tests. The relation-
ship between LAM ODs and indices of clinical prognosis,
mycobacterial burden and mortality was examined using box
and whisker plots and the corresponding medians were compared
using either Wilcoxon rank-sum tests or Kruskal-Wallis tests where
appropriate. Spearman rank correlation coefficients were used to
test the relationship between LAM ODs and several variables.
Results
Of 602 enrolled patients, 535 (88.9%) produced at least 1
sputum sample and 1 urine sample. Among those with both
sputum culture and LAM OD results available (n = 514), 84 cases
of sputum culture-positive TB were confirmed (prevalence 16.3%
[95%CI, 13.2–19.8]). Those with TB were young and the majority
was female (Table 1). The median CD4 cell count among these
patients was 138 cells/mL (IQR, 63–205) and the median plasma
viral load was 4.8 log copies/mL (IQR, 4.4–5.3).
Characteristics of patients grouped by LAM result and
corresponding OD
Among the 84 patients with HIV-associated TB, 23 (27.4%)
tested urine LAM-positive and 61 (72.6%) were LAM-negative.
The median OD among patients testing LAM-positive was 0.68
(IQR 0.16–2.43; range, 0.10–3.29). Of those with a positive LAM
result, 10 had a low OD (,0.50) while 13 had a high OD ($0.50).
The characteristics of patients were explored and groups whose
urine tested LAM-negative, LAM-positive (low OD) and LAM-
positive (high OD) were compared (Table 1). Increasing LAM
ODs across these groups were associated with lower CD4 cell
counts and haemoglobin levels and higher HIV viral loads, CRP
concentrations and blood neutrophil counts.
Relationship between LAM OD and indices of HIV disease
and clinical prognosis in patients with confirmed TB
We further explored the relationship between LAM OD and
markers of HIV disease progression and other prognostic indices
among all TB patients (n = 84) (Figure 1). LAM ODs were
substantially higher among those with the lowest CD4 counts (0–
49 cells/mL) (Figure 1a) and the highest levels of HIV plasma
viraemia (Figure 1b). LAM OD was also substantially higher
among patients with severe anaemia (Figure 1c), the highest
plasma CRP concentrations ($200 mg/L) (Figure 1d) and in
those with neutrophilia (.7.56109/L) (Figure 1e). No clear
association was observed between LAM OD and body mass index
(BMI) (Figure 1f).
Factors correlated with LAM ODs in LAM-positive
patients
Next we sought to determine which factors were correlated with
LAM ODs when analysis was restricted to those with a positive
LAM result and using continuous data. Since the data were not
normally distributed or linearly correlated with any variables
tested, non-parametric Spearman’s rank correlation coefficients
were used. Among 23 patients testing LAM-positive, absolute
Prognostic Value of Urine LAM Concentration
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Table 1. Characteristics of patients (n = 84) with confirmed tuberculosis (TB) stratified according to urine concentration of
lipoarabinomannan (LAM) expressed as ELISA optical density (OD).
All TB patients
(n=84) TB Patients categorised by urine LAM result* p-value
LAM-negative
(n =61)
LAM-positive: low OD
(n=10)
LAM-positive: high OD
(n=13)
Patient characteristics
Age (years), median (IQR) 33.1 (28.4–40.2) 34.4 (29.1–42.4) 30.1 (23.1–33.6) 29.4 (25.8–33.4) 0.022
Female, no. (%) 51 (60.7) 33 (54.1) 8 (80.0) 10 (76.9) 0.171
BMI (kg/m2), median (IQR) 21.2 (19.2–26.0) 21.4 (20.0–26.0) 19.8 (16.8–25.9) 19.8 (17.1–22.2) 0.112
Blood testsa
Haemoglobin (g/dL), median (IQR) 10.9 (8.8–12.4) 11.7 (10.3–13.0) 8.9 (7.9–9.9) 7.5 (7.0–8.4) ,0.001
C-reactive protein (mg/L), median (IQR) 54.1 (18.5–202.7) 37.9 (11.8–91.1) 125.7 (70.6–207.3) 207.4 (130.0) ,0.001
Absolute neutrophil count (x109/L), median
(IQR)
3.3 (2.4–5.0) 3.0 (2.0–4.0) 3.8 (2.5–5.0) 7.9 (4.4–11.5) ,0.001
CD4 cell count (cells/mL)b
Median 138 (63–205) 176 (100–214) 83 (30–145) 37 (10–112) ,0.001
,50 18 (21.7) 7 (11.7) 4 (40.0) 7 (53.9) 0.010
50–99 11 (13.3) 8 (13.3) 2 (20.0) 1 (7.7)
100–149 17 (20.5) 11 (18.3) 2 (20.0) 4 (30.8)
150–199 13 (15.7) 12 (20.0) 0 1 (7.7)
$200 24 (28.9) 22 (36.7) 2 (20.0) 0
HIV viral load (log copies/mL), median (IQR) 4.8 (4.4–5.3) 4.7 (4.2–5.1) 5.0 (4.7–5.5) 5.4 (5.2–5.6) ,0.001
aBlood test results available for 81 patients, bCD4 cell counts available for 83 patients; *LAM-negative patients had an OD,0.10, LAM-positive: low OD patients had an
OD $0.10 and ,0.50, LAM-positive: high OD patients had an OD$0.50.
doi:10.1371/journal.pone.0103285.t001
Figure 1. Box and whisker plot of urine concentrations of lipoarabinomannan (LAM) expressed as ELISA optical densities in
patients with HIV-associated tuberculosis stratified by indices of HIV disease progression and clinical prognosis: a) CD4 cell count
(n=83), b) log HIV viral load (n=84) c) WHO anaemia severity (n=81), d) C-reactive protein concentration (n=81), e) absolute
neutrophil count (n=81) and f) body mass index (n=84). Bars, box and whiskers indicate medians, 25th and 75th centiles and ranges,
respectively. P-values are either Wilcoxon rank-sum tests or Kruskal-Wallis for comparison of medians.
doi:10.1371/journal.pone.0103285.g001
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neutrophil count was the variable most strongly correlated with
LAM OD (Table 2). Both haemoglobin levels and CD4 cell
counts also demonstrated inverse correlations with LAM ODs but
other variables were not correlated with LAM OD. Thus, LAM
ODs correlated with more severe anaemia, CD4 lymphocytopenia
and neutrophilia.
Relationship between LAM OD and mycobacterial
burden
Among all patients with confirmed TB (n = 84), LAM ODs were
strongly associated with indices of mycobacterial burden in both
sputum and urine (Figure 2). Higher LAM ODs were observed in
patients with sputum smear-positive disease (Figure 2a) and in
those with the shortest times to sputum culture-positivity
(Figure 2b). LAM OD was also associated with detection of M.
tuberculosis bacilli in urine using the Xpert MTB/RIF assay
(Figure 2c). Combining sputum and urine results in a composite
index of mycobacterial burden also revealed a striking positive
association with LAM ODs (Figure 2d).
Relationship between LAM OD and mortality
Finally we sought to determine if LAM OD was associated with
mortality. Among 84 patients with confirmed TB, 5 (6%) patients
died within 3 months of enrolment. The median LAM OD among
patients who died was at least more than 6.8-fold higher than that
of patients who remained alive at 3 months (0.68 [IQR, 0.62–
2.43] versus ,0.10, respectively; p = 0.002). Of patients testing
urine LAM-positive with a high OD, 4 of 13 (31%) died compared
to 1 of 10 (10%) patients testing urine LAM-positive with a low
OD and none of the 61 (0%) patients who tested LAM-negative
(Chi-squared for trend; P = 0.006). However, the small number of
total deaths precluded assessment of comparative mortality risk in
groups stratified by low and high LAM OD results.
Discussion
In this study of HIV-infected patients with sputum culture-
positive TB, we found that higher concentrations of urine LAM (as
reflected by ELISA OD) were associated with extremely advanced
HIV disease progression and higher mycobacterial burden.
Furthermore, higher urine LAM concentrations were strongly
associated with a range of poor prognostic indices that are known
to be associated with increased mortality risk. Collectively, these
results suggest that a quantitative or semi-quantitative read-out of
urine LAM concentration may provide additional useful clinical
information.
Urine LAM testing may have an important role in the
diagnostic algorithm for HIV-associated TB. Although the overall
sensitivity of this assay is low, it nevertheless has highest sensitivity
among patients with advanced immunosuppression [9–12,14] and
moderate/severe anaemia [23]. Additionally, the availability of a
rapid, point-of-care assay version makes urinary LAM testing
much more user-friendly, permitting rapid initiation of TB
treatment at a single clinic visit for a proportion of patients [8].
While low overall sensitivity means that urine LAM assays are
inappropriate as stand-alone tests, high specificity make them
useful add-on tests within the TB diagnostic algorithm to quickly
‘rule-in’ and confirm TB [24]. A growing evidence base indicates
that a major strength of urine LAM testing is that LAM-positive
disease correlates with poor prognosis [12,13,25]. Therefore, a key
role for urinary LAM testing may be point-of-care diagnosis of TB
in the very sickest patients who urgently require immediate anti-
tuberculosis treatment. The present data further demonstrate that
having higher urine LAM concentration is very strongly associated
with adverse prognostic characteristics and might be used as an
indicator for the need for adjunctive interventions, including more
intensive treatment and follow-up.
High ELISA ODs were strongly associated with markers of very
advanced HIV disease, and high mycobacterial burden as
reflected by both sputum and urine assays. Since the Xpert
MTB/RIF assay detects DNA in whole Mycobacterium tubercu-
losis bacilli, urine testing positive by this assay indicates renal
involvement in patients with disseminated disease. It seems likely
that renal involvement in those with disseminated TB is also the
mechanism of LAM antigenuria. In support of this, it has been
previously demonstrated that higher LAM concentrations were
associated with mycobacteremia and were highest in those with
proven multi-compartmental disease [26]. Post-mortem studies
conducted throughout sub-Saharan Africa and India have shown
that between 38% and 67% of medical in-patients with HIV/
AIDS had evidence of TB at the time of death that was associated
with very high bacillary loads and widely disseminated disease with
multi-organ involvement [27–32]. Of note, several of these studies
reported that renal involvement with TB was extremely common
[28,29,32].
While LAM ODs were associated with several indices of poor
prognosis, the strongest correlation was with blood neutrophil
counts and the highest median LAM OD was seen in patients with
neutrophilia. Neutrophilia is directly associated with higher
mycobacterial burden [33] and is an independent predictor of
mortality in patients with TB [34]. It is not clear whether the high
neutrophil counts observed in LAM-positive patients reflect high
Table 2. Spearman’s rank correlation coefficients for factors associated with urine lipoarabinomannan (LAM) ELISA optical
densities among patients testing urine LAM positive (n = 23).
Spearman’s correlation coefficient p-value
Age, years 0.020 0.929
Female 0.175 0.425
Body mass index, kg/m2 0.302 0.161
Haemoglobin, g/dL 20.431 0.040
C-reactive protein, mg/L 0.209 0.340
Absolute neutrophil count,6109/L 0.599 0.003
CD4 cell count, cells/mL 20.414 0.050
HIV viral load, log copies/mL 0.255 0.240
doi:10.1371/journal.pone.0103285.t002
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mycobacterial load alone or are indicative of concurrent sepsis in a
proportion of these patients who have such advanced immuno-
suppression that they are at high risk for bacterial sepsis. Thus,
high LAM concentrations may potentially be indicative of a need
for adjunctive antibiotics in addition to anti-tuberculosis treatment
and trimethoprim-sulphamethoxazole prophylaxis.
Very high LAM ODs were seen in those with severe anaemia
and in those with greatly elevated CRP levels. Both of these
parameters are likely to be associated with high mycobacterial
burden and disseminated disease and are known to be associated
with mortality risk [23,35]. Patients who died within 3 months of
enrolment had much higher urine LAM concentrations than those
who survived. Four of the 5 patients who died had high LAM ODs
(.0.5). However, the small total number of deaths in this study
precluded assessment of comparative mortality risk of patients
testing urine LAM-positive with a low OD or a high OD. These
results suggest that not only is LAM-positivity predictive of very
poor clinical prognosis, but also that a LAM assay with a semi-
quantitative or quantitative read out may provide further
prognostic information. A larger study with a greater number of
deaths is needed to accurately define the relationship between
urine LAM concentration and mortality.
Determine TB-LAM is a low-cost, rapid, point-of-care assay
that has similar sensitivity and specificity to the laboratory-based
LAM ELISA for HIV-associated TB [9]. Although it is marketed
for use as a qualitative (positive/negative) assay, the read-out
displays a band of variable intensity that can be graded by
comparison to the included manufacturer’s reference card. This
might therefore provide a semi-quantitative result although use of
the assay in this way has not been validated. Increasing grade of
Determine-TB LAM may be directly correlated with higher LAM
ODs and poorer prognosis although these relationships remain to
be defined in future studies. It may be useful clinically if future
versions of this assay have two positive bands: one to indicate a
positive result with a low LAM concentration and another to
indicate a positive result with a high LAM concentration.
Study strengths include a well-characterised, unselected patient
cohort that was systematically screened for TB regardless of
Figure 2. Box and whisker plot of urine concentrations of lipoarabinomannan (LAM) expressed as ELISA optical densities in
patients with HIV-associated tuberculosis stratified by indices of mycobacterial burden: a) sputum smear microscopy result
(n =84), b) sputum culture days to positivity (n=84), c) urine Xpert result (n =84), d) a composite index combining sputum smear
microscopy and urine Xpert results (pos = positive; neg = negative). Bars, box and whiskers indicate medians, 25th and 75th centiles and
ranges, respectively. P-values are either Wilcoxon rank-sum tests or Kruskal-Wallis for comparison of medians.
doi:10.1371/journal.pone.0103285.g002
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clinical presentation as well as the use of liquid culture as a
reference standard for TB diagnosis. A range of prognostic indices
were examined and mortality risk was prospectively determined.
This study had some limitations. All patients had sputum culture-
positive disease and patients with isolated extrapulmonary disease
would not have been included. We quantified LAM in terms of
ELISA OD but did not determine absolute concentrations in
urine. Additionally, in the parent study, the Determine TB-LAM
assay read-out was qualitatively recorded as either a positive or
negative result and so the relationship between LAM ELISA OD
and the Determine TB-LAM POC assay positivity grade could not
be examined. Finally, due a small number of deaths occurring
among patients with confirmed HIV-associated TB, we were
unable to undertake a multivariable logistic regression analysis to
determine if urine LAM OD was independently associated with
mortality. Future studies among in-patients in whom mortality risk
is much higher may help to define this relationship further.
In conclusion, among patients with HIV-associated TB, urine
LAM is quantitatively associated with advanced HIV disease
progression, higher mycobacterial burden and poorer prognostic
characteristics that are known to be associated with increased
mortality risk. Urine LAM assays with a semi-quantitative or
quantitative read out may help to identify those with the poorest
prognosis and requiring adjunctive interventions. Such an assay
may therefore have increased clinical utility.
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